178 related articles for article (PubMed ID: 28893525)
1. [Doses to organs at risk in conformational and stereotactic body radiation therapy: Liver].
Debbi K; Janoray G; Scher N; Deutsch É; Mornex F
Cancer Radiother; 2017 Oct; 21(6-7):604-612. PubMed ID: 28893525
[TBL] [Abstract][Full Text] [Related]
2. [Hepatic tumors and radiotherapy].
Rio E; Mornex F; Peiffert D; Huertas A
Cancer Radiother; 2016 Sep; 20 Suppl():S174-8. PubMed ID: 27521035
[TBL] [Abstract][Full Text] [Related]
3. [Stereotactic body radiation therapy for hepatic malignancies: Organs at risk, uncertainties margins, doses].
Lacornerie T; Rio E; Mahé MA
Cancer Radiother; 2017 Oct; 21(6-7):574-579. PubMed ID: 28844506
[TBL] [Abstract][Full Text] [Related]
4. [Hippocampus, brainstem and brain dose-volume constraints for fractionated 3-D radiotherapy and for stereotactic radiation therapy: Limits and perspectives].
Gérard M; Jumeau R; Pichon B; Biau J; Blais E; Horion J; Noël G
Cancer Radiother; 2017 Oct; 21(6-7):636-647. PubMed ID: 28893524
[TBL] [Abstract][Full Text] [Related]
5. Hepatic tumours and radiotherapy.
Rio E; Mornex F; Maingon P; Peiffert D; Parent L
Cancer Radiother; 2022; 26(1-2):266-271. PubMed ID: 34953707
[TBL] [Abstract][Full Text] [Related]
6. [Dose constraints to organs at risk for conformational and stereotactic radiotherapy: Small bowel and duodenum].
Goupy F; Chajon E; Castelli J; Le Prisé É; Duvergé L; Jaksic N; Vogin G; Monpetit É; Klein V; de Bosschère L; Maingon P
Cancer Radiother; 2017 Oct; 21(6-7):613-618. PubMed ID: 28886980
[TBL] [Abstract][Full Text] [Related]
7. [Normal tissue tolerance to external beam radiation therapy: liver].
De Bari B; Pointreau Y; Rio E; Mirabel X; Mornex F
Cancer Radiother; 2010 Jul; 14(4-5):344-9. PubMed ID: 20598611
[TBL] [Abstract][Full Text] [Related]
8. [Stereotactic body radiation therapy in the management of liver tumours].
Jacob J; Nguyen F; Deutsch E; Mornex F
Cancer Radiother; 2014 Oct; 18(5-6):486-94. PubMed ID: 25195113
[TBL] [Abstract][Full Text] [Related]
9. [Doses to organs at risk in conformational radiotherapy and stereotaxic irradiation: The heart].
Vandendorpe B; Servagi Vernat S; Ramiandrisoa F; Bazire L; Kirova YM
Cancer Radiother; 2017 Oct; 21(6-7):626-635. PubMed ID: 28867460
[TBL] [Abstract][Full Text] [Related]
10. [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?].
Riou O; Valdenaire S; Debuire P; Fenoglietto P; Debrigode C; Mazard T; Assenat É; Aillères N; Azria D
Cancer Radiother; 2019 Oct; 23(6-7):636-650. PubMed ID: 31444078
[TBL] [Abstract][Full Text] [Related]
11. [Delineation of organs at risk and dose constraints].
Noël G; Antoni D; Barillot I; Chauvet B
Cancer Radiother; 2016 Sep; 20 Suppl():S36-60. PubMed ID: 27516050
[TBL] [Abstract][Full Text] [Related]
12. [Doses to organs at risk for conformational and stereotactic radiotherapy: Bladder].
Duvergé L; Castelli J; Lizée T; de Crevoisier R; Azria D
Cancer Radiother; 2017 Oct; 21(6-7):597-603. PubMed ID: 28882511
[TBL] [Abstract][Full Text] [Related]
13. [Follow-up after stereotactic body radiation therapy for liver tumours: A review of the literature and recommendations].
Janoray G; Mornex F
Cancer Radiother; 2015 Oct; 19(6-7):573-81. PubMed ID: 26341312
[TBL] [Abstract][Full Text] [Related]
14. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
[TBL] [Abstract][Full Text] [Related]
15. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.
Liang SX; Zhu XD; Xu ZY; Zhu J; Zhao JD; Lu HJ; Yang YL; Chen L; Wang AY; Fu XL; Jiang GL
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):426-34. PubMed ID: 16690430
[TBL] [Abstract][Full Text] [Related]
16. [Stereotactic body radiotherapy for liver tumors: State of the art].
Riou O; Azria D; Mornex F
Cancer Radiother; 2017 Oct; 21(6-7):563-573. PubMed ID: 28888744
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiosurgery and radiation therapy for spinal tumors.
Lo SS; Chang EL; Yamada Y; Sloan AE; Suh JH; Mendel E
Expert Rev Neurother; 2007 Jan; 7(1):85-93. PubMed ID: 17187488
[TBL] [Abstract][Full Text] [Related]
18. [Lung dose constraints for normo-fractionated radiotherapy and for stereotactic body radiation therapy].
Blais E; Pichon B; Mampuya A; Antoine M; Lagarde P; Kantor G; Breton-Callu C; Lefebvre C; Gerard M; Aamarcha A; Ozsahin M; Bourhis J; Maingon P; Troussier I; Pourel N
Cancer Radiother; 2017 Oct; 21(6-7):584-596. PubMed ID: 28886981
[TBL] [Abstract][Full Text] [Related]
19. [Limits of dose constraint definition for organs at risk specific to stereotactic radiotherapy].
Beddok A; Loi M; Rivin Del Campo E; Dumas JL; Orthuon A; Créhange G; Huguet F
Cancer Radiother; 2023 Jun; 27(4):341-348. PubMed ID: 37208260
[TBL] [Abstract][Full Text] [Related]
20. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma.
Xu ZY; Liang SX; Zhu J; Zhu XD; Zhao JD; Lu HJ; Yang YL; Chen L; Wang AY; Fu XL; Jiang GL
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):189-95. PubMed ID: 16542787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
